Examination of methylation changes of VIM, CXCR4, DOK7, and SPDEF genes in peripheral blood DNA in breast cancer patients

BACKGROUND: Studying whole blood DNA methylation as a risk marker has valuable applications in either diagnosis or staging of breast cancer. We investigated whole blood DNA methylation status of VIM, CXCR4, DOK7, and SPDEF genes in breast cancer patients in comparison to healthy control subjects. MA...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of cancer 2018-10, Vol.55 (4), p.366-371
Main Authors: Shirkavand, Atefeh, Boroujeni, Zahra, Aleyasin, Seyed
Format: Article
Language:English
Subjects:
Analysis
Biomarkers
Breast cancer
Cancer genetics
Cancer patients
Care and treatment
Cell adhesion & migration
Chemokines
Deoxyribonucleic acid
Development and progression
Diagnosis
DNA
DNA methylation
EDTA
Enzymes
Epigenetics
Gene expression
Genes
Genetic aspects
Genetic engineering
Kinases
Medical prognosis
Methylation
Polymerase chain reaction
Proteins
Studies
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND: Studying whole blood DNA methylation as a risk marker has valuable applications in either diagnosis or staging of breast cancer. We investigated whole blood DNA methylation status of VIM, CXCR4, DOK7, and SPDEF genes in breast cancer patients in comparison to healthy control subjects. MATERIALS AND METHODS: 60 patients with breast cancer and 40 healthy controls were examined. Genomic DNA isolated from peripheral blood and restriction enzyme polymerase chain reaction (REP) method was applied for analysis. Real-time PCR was used to confirm methylation status of the aforementioned genes and therefore to find out the methylation differences between normal and breast cancer subjects. RESULTS: Level of DOK7 promoter hypomethylation in normal and breast cancer samples was significant (P-value = 0.001). The study, also, showed that hypomethylation of VIM and CXCR4 genes are significant in patients compared with normal cases (P-value < 0.05). Furthermore, SPDEF promoter hypomethylation was not significantly differed between normal and breast cancer samples (P-value = 0.2). CONCLUSIONS: Hypermethylation of DOK7 gene in DNA from patients affected with breast cancer offers a biomarker for diagnosis of the breast cancer. This study indicates that methylation status of VIM and CXCR4 genes changes in breast cancer; so, they can be used as molecular biomarkers in breast cancer prognosis.
ISSN:0019-509X
1998-4774
DOI:10.4103/ijc.IJC_100_18